Dexcom Reports First Quarter 2026 Financial Results
Dexcom reported Q1 2026 revenue of $1.192 billion, representing 15% year-over-year growth on a reported basis, driven by healthy demand for its CGM systems. Profitability improved significantly, with GAAP operating income rising 850 basis points to 21.4% of revenue and non-GAAP operating income reaching $264.4 million.
Key figures
- Eps
- 0.51
- Revenue
- $1.192 billion
- Guidance
- FY2026 Revenue $5.16 - $5.25 billion; Non-GAAP Operating Margin approx 23-23.5%; Adjusted EBITDA Margin approx 31-31.5%
- Revenue Yoy
- 15%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.